Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery by unknown
Sánchez‑Sánchez et al. J Nanobiotechnol  (2015) 13:66 
DOI 10.1186/s12951‑015‑0127‑z
RESEARCH
Design of a VLP‑nanovehicle for CYP450 
enzymatic activity delivery
Lorena Sánchez‑Sánchez1, Alejandro Tapia‑Moreno2, Karla Juarez‑Moreno2,3, Dustin P. Patterson4, 
Ruben D. Cadena‑Nava2, Trevor Douglas5 and Rafael Vazquez‑Duhalt2*
Abstract 
Background: The intracellular delivery of enzymes for therapeutic use has a promising future for the treatment of 
several diseases such as genetic disorders and cancer. Virus‑like particles offer an interesting platform for enzymatic 
delivery to targeted cells because of their great cargo capacity and the enhancement of the biocatalyst stability 
towards several factors important in the practical application of these nanoparticles.
Results: We have designed a nano‑bioreactor based on the encapsulation of a cytochrome P450 (CYP) inside the 
capsid derived from the bacteriophage P22. An enhanced peroxigenase, CYPBM3, was selected as a model enzyme 
because of its potential in enzyme prodrug therapy. A total of 109 enzymes per capsid were encapsulated with a 70 % 
retention of activity for cytochromes with the correct incorporation of the heme cofactor. Upon encapsulation, the 
stability of the enzyme towards protease degradation and acidic pH was increased. Cytochrome P450 activity was 
delivered into Human cervix carcinoma cells via transfecting P22‑CYP nanoparticles with lipofectamine.
Conclusion: This work provides a clear demonstration of the potential of biocatalytic virus‑like particles as medical 
relevant enzymatic delivery vehicles for clinical applications.
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Background
The therapeutic use of enzymes is a fast growing field 
that is the focus of extensive research from several 
groups and pharmaceutical companies worldwide. The 
interest in this class of biopharmaceuticals has dramati-
cally increased and it is changing the way several diseases 
will be treated, since their mode of action involves highly 
specific and efficient catalysts. Therapeutic enzymes 
have been proposed to treat several illnesses including 
genetic diseases, infectious diseases and cancer [1–3]. A 
great proportion of the enzymes that are already in use 
work extracellularly; nevertheless to efficiently treat the 
above mentioned diseases, in particular genetic disor-
ders and cancer, enzymes have to be internalized within 
the cell to reach their therapeutic target. Two significant 
therapeutic approaches based on enzymes have been 
proposed. In Enzyme Replacement Therapy (ERT) [4–6] 
an enzyme is exogenously provided to replace a missing 
enzyme, while in Enzyme Prodrug Therapy (EPT) [7–9] 
an enzyme capable of activating a pro-drug into its active 
metabolites is delivered. In both of these therapies there 
is a need for suitable vehicles to deliver these therapeutic 
enzymes intracellularly to targeted cells, while avoiding 
rapid inactivation and elimination from the body [10].
Virus-like particles (VLPs) offer an interesting plat-
form as potential therapeutic agents for such intracellular 
delivery of enzymatic activity for several reasons includ-
ing their ability to load and transport significant quanti-
ties of enzymes, their intrinsic capacity to protect their 
cargo and the ease with which they can be chemically and 
genetically modified [11]. Until now the encapsulation of 
enzymes inside VLPs has been useful to study biocataly-
sis in confined environments. Sequestration of enzymes 
within these vehicles can lead to high internal concentra-
tions of cargo, in the mM range, difficult to reach with 
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enzymes free in solution. Additionally, with the confine-
ment of enzymes inside these viral nanoparticles, new 
features are generated in the resulting nanoreactor, such 
as improvements in stability towards temperature or pro-
tease degradation [12–18].
One of the most well studied VLPs is the one derived 
from the bacteriophage P22. It is a 58  nm icosahedral 
capsid composed of 420 coat proteins (CP) that assem-
bles with the aid of 60–300 scaffold proteins (SP) [19]. It 
has been used to encapsulate several enzymes with high 
cargo density [15–18]. The strategy used to incorporate 
the enzymes into the interior of the P22 capsid requires 
genetically fusing the desired enzyme to the N-terminus 
of a truncated form of the scaffold protein, which is still 
capable of interacting non-covalently with the interior of 
CP and directing capsid assembly [20].
The aim of the work presented here was to encapsulate 
a cytochrome P450 (CYP), which belongs to a family of 
medically and industrially important enzymes, to cre-
ate a nanovehicle with high catalytic activity. The vari-
ant “21B3” of CYPBM3 from Bacillus megaterium, with 
improved peroxigenase activity [21], was used as a model 
of this family of enzymes since it is stable and soluble in 
aqueous media, and it can be produced in large quan-
tities, in contrast to human CYPs. Moreover, several 
mutants of this CYPBM3 have been generated which 
facilitate the enzymatic transformation of non-natural 
substrates such as pesticides [22], polycyclic aromatic 
hydrocarbons [23], and drugs [24], suggesting potential 
environmental and pharmaceutical applications. Interest-
ingly, in a previous report we found that CYPBM3 “21B3” 
was able to transform the potential prodrug resveratrol 
as well as the anti-carcinogenic prodrug tamoxifen, one 
of the most commonly used drugs to treat breast cancer, 
into their clinically active metabolites [25].
Results and discussion
The P22 coat protein (CP) and the CYPBM3-scaffold 
fusion protein (CYP-SP) were heterologously expressed 
in E. coli. Two different strategies for the in vivo assembly 
of the VLPs with encapsulated enzyme were used; simul-
taneous expression of the coat protein and CYP-SP, and 
differential expression of the enzyme and CP. In the lat-
ter, a two-vector approach exploited the use of different 
inducers to drive first the expression of CYP-SP, allowing 
maturation of the enzyme, and then initiation of encap-
sulation by inducing expression of the CP. Correctly sized 
capsids with cargo were produced using both approaches; 
however, the proportion of active cytochrome was much 
higher when the genes were differentially expressed 
(Table 1). We were able to quantify the concentration of 
active enzyme inside the capsids estimating the amount 
of CYP able to form the carbon monoxide-heme FeII 
complex, which produces an absorbance spectrum with a 
maximum wavelength at 450 nm [26]. On the other hand, 
the total protein was estimated from the absorbance at 
280 nm and multiangle light scattering data (see below). 
By these means we were able to distinguish between cata-
lytically active CYP and non-active enzyme. The maxi-
mum theoretical number of encapsulated CYPs (3.3 nm 
hydrodynamic radius) per P22 particle, based on volume, 
is around 180 enzymes. Co-expression showed the high-
est CYP loading, near this maximum number, but with a 
lower percentage of active enzyme. The fast interaction of 
the CYP polypeptide chain with the CP could be affecting 
the integrity of the enzyme as showed by the large pro-
portion of inactive enzyme (93 %).
Differential expression was performed using two differ-
ent strategies. In the first case, 0.2 % l-arabinose was used 
to induce expression from the CYP-SP gene and 0.5 mM 
IPTG to induce the CP gene expression. In the second 
case, 0.125 % l-arabinose was used to induce expression 
of the CYP-SP gene and 0.3 mM IPTG to induce the CP 
gene. By lowering the concentration of inducers we were 
able to increase the percentage of active CYP without sig-
nificantly affecting the amount of encapsulated enzyme 
per capsid (Table 1). Thus, in the differential expression 
strategy the number of active enzymes per capsid could 
Table 1 Comparison between expression systems for the encapsulation of CYPBM3 inside P22
a Determined by Eq. 1
b Total CYP determined using an extinction coefficient at 280 nm assuming a molar extinction coefficient ε280 = 44,920 M−1 cm−1 for coat protein and 
ε280 = 52,830 M−1 cm−1 for CYP‑SP (theoretically calculated using ProtParam, Gasteiger, 2005). The concentration of protein was calculated using the Lambert–Beer 
equation, AbsT = CCP·ɛCPl + CCYP‑SP·ɛCYP‑SPl as described previously [15]
c Active CYP determined by the formation of CO‑CYP complex in reducing medium with a extinction coefficient of ε450 = 0.091 nM−1cm−1 [26]
d Active/total CYP ratio expressed in percentage






Co‑expression (pETDuet) 156.0 (±0.4) 123.5 9.2 7
Differential expression 1 (pBAD + pRSF) 129.5 (±0.1) 135.3 31.8 23
Differential expression 2 (pBAD + pRSF) 109.7 (±2.8) 123.7 42.9 35
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be improved by tuning expression parameters, such as 
induction time and concentration of inducers.
In order to determine if all CYP molecules were 
expressed as holoenzymes, and explain the signifi-
cant difference in concentration values encountered by 
absorbance at 280 and the CO assay, the iron concen-
tration present in encapsulated CYPs was determined 
by Inductively Coupled Plasma Mass Spectrometry 
(ICP-MS). Samples from the second differential expres-
sion strategy showed a complete incorporation of iron-
heme cofactor (CYP:Fe molar proportion of 1:1) in all 
encapsulated CYPs, in which only 35  % were observed 
to be active by the carbon monoxide binding assay. 
This suggests that the other two-thirds of encapsulated 
enzyme could be trapped as misfolded intermediates 
where the iron of the heme group is bound, but in an 
incorrect coordination state [27]. This could be due to 
the fast interaction of CYP-SP with the CP, disrupting 
the CYP folding before the correct incorporation of the 
heme prosthetic group, as supported by the low propor-
tion of active CYP found in the co-expression strategy 
(Table 1).
The biocatalytic VLP preparations, with the highest 
proportion of active CYP, corresponding to the second 
strategy (differential expression) were further character-
ized structurally and kinetically. VLPs were produced in 
high yields of 120 mg of P22-CYP VLPs per liter of cul-
ture, and were easily purified. Highly monodisperse VLP 
preparations were obtained, with an average VLP diam-
eter of 53.6  ±  0.2  nm as determined by HPLC-MALS-
RI. The amount of encapsulated CYP per capsid was 
109.7 ± 2.8 CYP molecules per particle as determined by 
HPLC-size exclusion chromatography coupled to in-line 
multi-angle laser light scattering (MALS) and refractive 
index (RI) detectors (Fig. 1a). As confirmed by TEM, the 
nanoparticles are quasi-spherical and well structured, 
suggesting that the packaging of the enzyme did not 
have any repercussions on the assembly of the P22 capsid 
(Fig. 1b).
Compared to other recently designed nanovehi-
cles for enzyme intracellular delivery, P22-CYP VLPs 
showed a higher enzyme content of 40  % (w/w) of the 
total nanoparticle weight, demonstrating a higher pay-
load capacity, compared to 16.7  % in a superoxide dis-
mutase-mesoporous silica nanoparticle system [28] and 
15  % in a nanoparticle formed by the conjugation of 
β-galactosidase with enhanced green fluorescent protein 
[29].
The catalytic constants for the encapsulated and free 
CYPBM3 were determined (Table  2). For both prepara-
tions, only the catalytically active enzyme was considered 
for the kcat and KM calculations. The catalytic constants 
are apparent since we could not reach the saturation 
concentration of peroxide. The enzyme was rapidly inac-
tivated in the presence of high concentrations of hydro-
gen peroxide (>60  mM), as previously reported [21]. In 
addition, at such high peroxide concentrations, substrate 
oxidation seems to be affected by a possible Fenton-like 
reaction (data not shown).
Encapsulated CYP showed a 70  % catalytic rate (kcat) 
compared to that found with the free enzyme, while its 
affinity constant (KM) for hydrogen peroxide was slightly 
higher when compared to the free enzyme. Thus, the 
catalytic efficiency (kcat/KM) found for the encapsulated 
enzyme is around half of the free enzyme. The diffusion 
coefficients of P22-CYP VLPs and free CYP were calcu-
lated according to [30] using a hydrodynamic radius of 
26.8 nm and 3.3 nm, respectively. The resulting diffusion 
Fig. 1 Structural characterization of P22‑CYP VLPs. a Size exclusion chromatogram with molecular weight analysis by HPLC‑MALS‑RI. Black line light 
scattering intensity. Red line molecular weight (Da). b Transmission electron micrograph of P22 capsids with encapsulated CYP
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coefficients were 8.06 ×  10−12  m2  s−1 for P22-CYP and 
6.55 × 10−11 m2 s−1 for the free enzyme.
The decrease in catalytic activity of encapsulated 
enzymes has been reported for other VLP-enzyme systems 
[13, 15, 17, 31], and has been mainly attributed to diffu-
sional problems and to a decrease in the structural flex-
ibility of enzymes as a result of a highly crowded space. 
The diffusion rate of substrates through VLP pores could 
affect their transformation rates. It depends on several fac-
tors such as the hydrodynamic radius of the substrates, the 
pore diameter and the electrostatic environment around 
the capsid pores, as well as the degree of obstruction of the 
pores by the cargo enzyme. Comellas-Aragones et al. [12] 
showed a diffusion time increase of almost three orders 
of magnitude for rhodamine when it had to pass through 
the 2 nm pores present in CCMV capsids, when compared 
to the substrate diffusion time in distilled water. Another 
limiting factor related to mass transfer phenomena is the 
decrease, by one order of magnitude, of the diffusion coef-
ficient of P22-CYP compared to the free enzyme. This 
likely affects the rate of collisions between enzyme and 
substrate molecules influencing the kinetics.
On the other hand, the high degree of confinement 
found inside the capsids, in our case Mconf =  3.14  mM 
(capsid internal volume of 5.8 × 10−20 L), could restrict 
the conformational changes needed to perform catalysis. 
It is well known for this particular CYP that the F and 
G helices undergo important structural motion while 
executing catalysis [32] that could be impaired by the 
high degree of confinement. A decrease in activity using 
other immobilization materials, such as sol–gel matrices 
and DEAE resins, has also been reported for the heme 
domain of CYPBM3 as well for the whole protein [33, 34] 
suggesting that this enzyme is sensitive to motion impair-
ment. The fact that CYPBM3 was expressed as a fusion 
protein with a fragment of the P22 scaffold protein could 
also have affected its kinetic behavior. Further evalua-
tion of the structural dynamics of this CYP inside the 
P22 capsid are needed to better understand and explain 
the particular changes observed in the catalytic param-
eters. Moreover, given the importance that diffusion may 
impose in the system for relevant therapeutic treatments 
this issue should be assessed.
Due to their confinement, it could be expected that 
enzyme stability against therapeutically important fac-
tors could increase. Enzyme stability towards protease 
degradation and to pH were assayed (Fig. 2). CYPBM3 
encapsulation inside P22 capsid confers protection of 
the cargo enzyme against proteases. After 1-h incuba-
tion in the presence of trypsin, the residual activity of 
the encapsulated CYP was 90.3 % while the free enzyme 
retained only 59.5  % of its original activity. After 20  h 
of incubation with the protease, the retention of activ-
ity for the P22-CYP was 36.1 %, while the free enzyme 
retained only 18.2  % (Fig.  2a). This intrinsic capacity 
of viruses to protect their cargo from proteolytic deg-
radation can be exploited in the use of these VLPs as 
enzyme delivery vehicles for therapeutic purposes, 
Table 2 Apparent catalytic constants for free and encapsu-
lated CYPBM3
a The reaction mixture contained a catalytic saturating concentration of 500 µM 
2,6‑DMP
kacat (min
−1) KM (H2O2) (mM) kcat/KM  
(min−1 mM−1)
P22‑CYP 507.9 (±37.1) 25.2(±4.2) 20.1
Free CYP 720.5 (±27.8) 18.5 (±1.8) 38.9
Fig. 2 Comparison between free and encapsulated CYP against protection from protease inactivation and acidic pH stability. a Residual CYP activ‑
ity after incubation of P22‑CYP and free CYP with 10 U of trypsin per mg of protein during 1 and 20 h. b Residual CYP activity after incubation of 
P22‑CYP and free CYP in pH 5 and pH 6 for 1 h. CYP activity was measured at 100 mM Tris–HCl pH 8 buffer using 2,6‑DMP as a substrate and 5 mM 
of H2O2 to initiate the reaction. Treatments were analyzed by one‑way ANOVA and multiple comparisons between mean values using Turkey’s test. 
All values showed to be statistical different (*p < 0.01)
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ensuring a higher lifetime of cargo in  vivo. Moreover, 
this increase in the proteolytic stability is particularly 
important in cancer therapy. It is well known that there 
is an overexpression of extracellular matrix metallopro-
teinases (MMPs) in the tumor microenvironment. The 
MMPs are involved in cell growth, tissue invasion and 
metastasis, angiogenesis and migration, among oth-
ers processes, and they role is to cleavage a variety of 
extracellular matrix components (adhesion molecules), 
growth-factor-binding proteins, growth-factor precur-
sors, receptor tyrosine kinases, cell-adhesion molecules 
and other proteases [35]. The proteolytic stability of 
VLPs has been reported [36, 37] and could be originated 
by less accessible hydrolysis sites due to new bond for-
mation in the compact VLP structure. It is important to 
point out that for further in vivo experiments, the VLPs 
will be covalently covered with PEG that, in addition to 
render them less immunogenic, it could be envisaged a 
higher proteolytic stability.
Another advantage of CYPBM3 confinement inside the 
P22 viral cage is an increase in stability towards acidic 
pH, where the free CYP precipitates. The encapsula-
tion of the enzyme prevents its precipitation at pH 5 and 
retains, after 1-h incubation, 33.3 % of its original activ-
ity, while the free soluble CYP retains only 2.9 % of activ-
ity. After 1-h incubation at pH 6, the encapsulated CYP 
retains full activity, while the free preparation loses 25 % 
of its original activity (Fig.  2b). The isoelectric point of 
the free CYPBM3-His Tag was 5.4 (experimentally calcu-
lated; data not shown), while the CYP-SP had a pI = 6.1 
(theoretically calculated using ProtParam), this shift in 
pI could help to prevent the precipitation of the encap-
sulated enzyme. Also, the encapsulation of the enzyme 
within the capsid avoids bulk precipitation and subse-
quent aggregation of the CYPBM3, therefore retaining 
a higher proportion of activity. This increased stabil-
ity towards acidic pH is of particular importance from 
a therapeutic point of view, since the majority of nano-
particles are internalized by cells through an endocytic 
pathway, with early endosomes having a pH in the range 
of 6–6.5 and late lysosomes having a pH between 4.5 
and 5.5 [38]. Moreover, the extracellular environments 
of tumors are known to be acidic (6.5–6.9) due to the 
increase in fermentative metabolism [39]. Thus, the effect 
of acidic pH on CYP can be relieved by its encapsulation 
inside the P22 capsid.
To evaluate whether P22-CYP VLPs were suitable vehi-
cles for the intracellular delivery of cytochrome P450 
activity, HeLa cells were transfected with the biocata-
lytic nanoparticles, which were then tested for enzymatic 
activity using 7-benzyloxy-4-trifluoromethylcoumarin 
(BFC) as a substrate. When BFC is metabolized into 
7-hydroxy-4-trifluoromethylcoumarin (HFC) it produces 
an easily detectable fluorescent product (Fig. 3). The fluo-
rescence intensity of cells treated with P22-CYP was sig-
nificantly higher when compared to those observed from 
endogenous CYP activity in untreated HeLa cells. BFC 
processing into the fluorescent HFC reagent was clearly 
localized in the cytoplasmic region as expected, since 
lipofectamine was used for nanoparticle internalization 
given the lack of P22 surface functionalization for mam-
malian cell uptake.
Fig. 3 Cytochrome P450 activity assay in human cervix carcinoma cell line (HeLa). Staining with DAPI show nuclei of HeLa cells labeled as “n”, 
panels a and d. Endogenous CYP activity over BFC reagent was visualized in HeLa cells as observed in panel b. CYP activity of transfected VLPs‑CYP 
nanoparticles in HeLa cells is shown in panel e. Overlay of DAPI and BFC localize the CYP activity in the cytoplasm of HeLa cells (white arrows), panels 
c and f. Scale bar represents 20 μm. Cells were visualized with a ×63 (DIC), 1.4 N.A. planapochromatic oil immersion objective
Page 6 of 10Sánchez‑Sánchez et al. J Nanobiotechnol  (2015) 13:66 
In addition, CYP activity was quantitatively determined 
as fluorescence intensity. BFC is a specific substrate for 
CYP and it is transformed to 7-hydroxy-4-trifluoro-
methylcoumarin (HFC) that produces an intense fluores-
cence at 510 nm. As expected, the control cells showed a 
basal endogenous CYP activity (110 ± 14 a.u.) while the 
P22-CYP transfected cells showed 10-times higher CYP 
activity (1136 ± 244 a.u.) (Fig. 4). Experiments with free 
CYP in the same reaction conditions showed a linear cor-
relation between fluorescence of HFC and CYP activity. 
This result demonstrates the capacity of VLPs to deliver 
enzymatic activity to cells. With the increase of CYP 
activity in tumor cells, it is expected a better pro-drug 
activation in the target tissue and thus a more effective 
chemotherapy. This is important because the drug dose 
could be diminished, reducing the drastic side effects of 
treatment. Tamoxifen is metabolized to endoxifen, which 
has high affinity for estrogen receptor with the desired 
chemotherapeutic effect, but norendoxifen does not have 
the desired effect with extreme side effects. Approxi-
mately 20 % of the population has low CYP2D6 activity 
that renders tamoxifen less effective. The cellular uptake 
of tamoxifen by MCF-7 breast cancer cells is known [40] 
and because the estrogen receptors are located in the 
periphery of the nuclear membrane, these nanoparticles 
could provide increased therapeutic benefit by trans-
forming tamoxifen to the active drug inside cells and 
binding to ER receptors.
Future studies on these biocatalytic P22 VLPs will be 
required to functionalize the outer surface of the capsid 
with specific ligands to target specific cells and trigger 
internalization as well as to bypass the immune system. 
Fortunately, there are abundant strategies being devel-
oped to target nanoparticles to specific cell linages [41–
43] that are compatible with VLP functionalization.
Conclusions
The P22 viral nanostructures are remarkable protein con-
tainers, as demonstrated in this study, where biocatalytic 
VLPs were generated based on the directed encapsula-
tion of CYPBM3 “21B3”. This nanobioreactor contains a 
considerable amount of CYP per capsid. The CYP cargo 
retains 70 % of the catalytic activity, and showed a slightly 
higher KM as compared to the free enzyme. New unique 
properties, including protease resistance and stability in 
acidic pH, were generated through the encapsulation of 
the CYP inside the P22 capsid. These two improved char-
acteristics of the biocatalytic VLP over the free enzyme, 
along with a great payload capacity and the successful 
proof of concept of cytochrome P450 enzymatic delivery 
in mammalian cells, are attractive for the potential use 
of these nanoreactors as enzymatic delivery systems for 
future therapeutic applications.
This potent CYP nanobioreactor can be exploited for 
enzyme prodrug therapy, particularly to activate anticar-
cinogeneic drugs into its active metabolites since it out-
performs the generally low activities of human CYP. The 
P22-CYP nanobioreactor also provides a unique model 
for the study of kinetics in highly constrained environ-
ments, such as the one found inside the VLP.
Methods
Materials
DNA primers and DNA sequencing were obtained 
from Eurofins MWG Operon (Huntsville, AL). E. coli 
BL21(DE3) and 10G electrocompetent E. coli cells were 
purchased from Lucigen (Middleton, WI). Pfu Ultra 
DNA polymerase was obtained from Agilent Technolo-
gies (Santa Clara, CA). T4 DNA ligase and restriction 
enzymes NcoI, BamHI and SacI were purchased from 
New England Biolabs (Ipswich, MA). MiniElute Reaction 
Cleanup Kit, QIAquick Gel Extraction Kit and QIAprep 
Spin Miniprep kit were acquired from Qiagen (Valen-
cia, CA). Hydrogen peroxide, 2,6-dimethoxyphenol (2,6-
DMP) and 7-benzyloxy-4-(trifluoromethyl)-coumarin 
(BFC) were purchased from Sigma-Aldrich (St. Louis, 
MO). Trypsin from bovine pancreas (Type I, ~10,000 
BAEE units/mg protein) was obtained from Sigma-
Aldrich (St. Louis, MO).
Expression and purification of free CYPBM3 “21B3”
The plasmid pCWori encoding the heme domain of 
the CYPBM3 “21B3” was a kind gift from Prof. France 



















Fig. 4 Cytchrome P450 enzymatic activity of transfected HeLa cells. 
The activity of endogenous CYP and lipofected P22‑CYP VLP in HeLa 
cells was measured by the transformation of BFC reagent into the 
fluorescent HFC compound. Intensity in fluorescence was obtained in 
both cases from a 200,000 cells suspension with an excitation/emis‑
sion spectra at 254/510 nm. Stastistical significance was analyzed by 
the Student’s t test (*p < 0.01)
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(Caltech). The CYPBM3 mutant 21B3 was expressed 
in E. coli using the β-d-thiogalactopyranoside (IPTG)-
inducible pCWori vector as previously described [21]. 
CYPBM3 “21B3” purification was performed by chro-
matography in an EconoSystem from Bio-Rad equipped 
with a 5 mL Ni-pre-charged HisTrap HP column (Amer-
sham Biosciences). The equilibration buffer consisted in 
50 mM NaH2PO4, 300 mM NaCl and 10 mM imidazole, 
pH 8. The protein mixture was loaded at 1.5 mL min−1. 
The CYP protein was eluted in a buffer containing 
300 mM imidazole at 3 mL/min for 10 min. The colored 
fractions were collected, concentrated by ultrafiltration 
and stored at −20  °C in 50 mM Tris–HCl buffer, pH 8, 
containing 10 % glycerol. CYP protein concentration was 
determined by using the CO assay [26].
Plasmid constructs
The CYPBM3 “21B3” gene was amplified by PCR from 
the plasmid pCWori CYBM3 using the forward primer, 
5 ′-AAAAATCATGCCATGGCAATTAAAGAAAT 
GCCT-3′ and reverse primer, 5′-AAAAAAGCGGGATCC 
AGTGCTAGGTGAAGGAA-3′.
The amplified gene product was digested with NcoI and 
BamHI (underlined in primer sequences, respectively) 
and ligated into the previously linearized pETDuet-1 
assembler vector containing the truncated scaffold pro-
tein SP141–303 and the P22 coat protein [16]. The ligation 
reaction was transformed into 10G electrocompetent 
cells and colonies were screened by colony PCR and 
restriction enzyme digestion. Hits were sequenced 
(Huntsville, AL) to confirm the correct DNA sequence. 
Once the correct sequence was verified, the pETDuet 
CYP-SP+CPP22 plasmid (AmpR) was transformed into 
BL21(DE3) for the simultaneous expression strategy. The 
fusion CYPBM3 “21B3”—scaffold protein (CYP-SP) gene 
was subcloned from the pETDuet CYP-SP  +  P22 into 
the pBAD plasmid. The pETDuet CYP-SP  +  P22 plas-
mid and pBAD vector were both digested with NcoI and 
SacI. The digested products were ligated and transformed 
into 10G electrocompetent cells. Colonies were screened 
by colony PCR and restriction enzyme digestion. Hits 
were sequenced (Huntsville, AL) to corroborate for the 
right DNA sequence. Once the correct sequence was 
verified, the pETDuet CYP-SP + CPP22 plasmid (AmpR) 
and the pRSF P22 plasmid (KmR) were transformed into 
BL21(DE3) for the differential expression strategy.
Simultaneous protein expression strategy
E. coli BL21(DE3) cells harboring the expression plasmid 
pETDuet CYP-SP+CPP22 were grown on Terrific Broth 
(TB) medium, supplemented with 0.5  mM thiamine 
and trace elements, at 37  °C and 180  rpm in the pres-
ence of ampicillin to maintain selection for the plasmid 
until reaching and OD600  =  0.8. At this point, 0.5  mM 
of isopropyl-β-d-1-thiogalactopyranoside (IPTG) and 
1  mM δ-aminolevulinic acid were added. Cell cultures 
were grown for additional 5 h at 30 °C and 135 rpm, then 
cells were harvested by centrifugation and the pellets 
stored at −20 °C overnight until purification.
Differential protein expression strategy
E. coli BL21(DE3) cells harboring the expression plas-
mids pBAD CYP-SP and pRSF P22 were grown on TB 
medium, supplemented with 0.5 mM thiamine and trace 
elements, at 35 °C and 150 rpm for 7 h in the presence of 
ampicillin and kanamycin to maintain selection for both 
plasmids. At this point, two different induction schemes 
were followed: (1) The CYP-SP gene was induced first 
with 0.2  % of l-arabinose and the culture was supple-
mented 1  mM δ-aminolevulinic acid. The cell culture 
was grown for 16 h. After this period of time, the CPP22 
gene was induced with 0.5 mM of IPTG and the cultures 
were grown for 3 additional hours at 30 °C and 150 rpm, 
then cells were harvested by centrifugation and the pel-
lets stored at −20 °C. (2) The differential expression was 
performed as stated above but the expression of the CYP-
SP gene was induced with 0.125 % of l-arabinose and the 
P22 with 0.3 mM IPTG.
P22‑CYP VLP purification
Cell pellets were resuspended in lysis buffer (50  mM 
sodium phosphate, 100  mM sodium chloride, pH 7.6) 
and lysed by sonication. Cell debris were removed by 
centrifugation at 12,000×g for 45 min at 4 °C. P22 VLPs 
were purified from the supernatant by ultracentrifugation 
over a 35 % (w/v) sucrose cushion and spun at 215,041×g 
on a Sorvall WX Ultra 80 ultracentrifuge (Thermo 
Scientific) for 50  min at 4  °C. The resulting P22 VLP 
pellet was resuspended in PBS (50  mM sodium phos-
phate, 25  mM sodium chloride, pH 7.0) and then puri-
fied over a 60 ×  1.6  cm HiPrep 16/60 Sephacryl S-500 
size exclusion column (GE Helathcare) using an AKTA 
Pharmacia FLPC. Flow rate for SEC purification was 
1 mL min−1 of PBS. Fractions taken from SEC contain-
ing P22 VLPs were concentrated by ultracentrifugation 
at 215,041g for 50  min at 4  °C and the resulting capsid 
containing pellet was resuspended in 100 mM Tris–HCl 
pH 8 buffer. The purity of VLPs has been verified by gel 
electrophoresis and transmission electron microscopy 
(TEM). P22 VLPs concentration was determined by UV 
absorption at 280  nm using a molar extinction coef-
ficients of ε280 =  44,920 M−1  cm−1 for coat protein and 
ε280  =  52,830  M−1  cm−1 for CYP-SP (theoretically cal-
culated using ProtParam, [44]). The total concentration 
of protein in the P22 capsid with encapsulated CYP-SP 
(P22-CYP VLPs) was calculated using the Lambert–Beer 
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equation, AbsT  =  CCP·ɛCP·l  +  CCYP-SP·ɛCYP-SP·l as 
described previously [15]. AbsT is the total absorbance of 
the sample measured at 280 nm.
Size exclusion chromatography with multiangle light 
scattering and refractive index detection (HPLC‑MALS‑RI)
Samples were separated through a WTC-100S5 (Wyatt 
Technologies) size exclusion column utilizing an Agi-
lent 1200 HPLC. Elution was performed at flow rate 
of 0.7  mL  min−1, for a total run time of 25  min using 
50  mM phosphate pH 7.2 buffer containing 100  mM 
sodium chloride and 200 ppm sodium azide. Samples of 
25 µL (1 mg mL−1 concentration) were loaded into the 
column and the total run time was 30 min. Samples were 
detected using a UV–Vis detector (Agilent), a Wyatt 
HELEOS Multi Angle Laser Light Scattering (MALS) 
detector, and an Optilab rEX differential refractometer 
(Wyatt Technology Corporation). The molecular weight 
of the P22-CYP VLPs, the polydispersity of the sample 
as well as the hydrodynamic radius of the particle was 
calculated with Astra 5.3.14 software (Wyatt Technology 
Corporation).
The number of enzymes encapsulated within a P22 
VLP was calculated using the following formula
where M(P22capsid+CYP-SP) is the molecular weight of the 
capsid with the encapsulated CYP-SP (determined exper-
imentally with HPLC-MALS-RI), Mcapsid is 19,572  kDa 
(46.6 kDa × 420 subunits) and MCYP-SP is 71.5 kDa (calcu-
lated with Serial Clones 2.6, Franck Perez, Serial Basics).
Transmission electron microscopy
VLPs (10 µL, 0.1 mg mL−1) were applied to carbon-form-
var coated grids and incubated for 1 min, excess sample 
was removed with Whatman filter paper. Grids were then 
washed with 10 µL of distilled water, removing away liq-
uid shortly after addition with filter paper and stained 
with 5 µL 1 % uranyl acetate for 1 min. Excess stain was 
removed by blotting with filter paper. Samples were ana-
lyzed with a LEO 912AB transmission electron micro-
scope operated at 100 kV.
Inductively coupled plasma‑mass spectrometry (ICP‑MS)
A P22-CYP VLP sample (21.6 mg) was incubated in con-
centrated nitric acid (HNO3) for 16 h at 70 °C. After sam-
ple mineralization, it was diluted with water to a final 
HNO3 concentration of 5 % in a final volume of 50 mL. 
Samples were sent to Energy Laboratories, Inc (Billings, 
MT, USA) to be analyzed. Sulfur was used as internal 
(1)
CYP − SPpercapsid =
M(P22capsid+CYP−SP) −M(capsid)
M(CYP−SP)
reference (8401 sulfur atoms per P22-CYP capsid) for 
determining the ratio of iron to protein.
Free CYP and P22‑CYP kinetic assays
The CYP enzymatic activity was determined by 
the transformation of 2,6-dimetoxyphenol (2,6-
DMP) and spectrometrically monitored at 468  nm 
(ɛ468  =  14,800  M−1  cm−1) using an Agilent 8453 
UV-Vis spectrophotometer. All reactions were performed 
in 50 mM Tris–HCl buffer (pH 8) at room temperature in 
a final volume of 0.1 mL. For the determination of cata-
lytic parameters the concentration of 2,6-DMP was fixed 
at 500 µM. The reaction was initiated by adding H2O2 in 
a range between 1 and 60 mM. Catalytic constant values 
were obtained by fitting the data to a Michaelis–Menten 
equation (GraphPad Prism 6, GraphPad Software, Inc.).
P22‑CYP VLPs stability against acidic pH
The residual activity of free CYP and P22-CYP was meas-
ured at pH 5 (100 mM sodium acetate buffer) and pH 6 
(100  mM potassium phosphate buffer), incubating the 
samples for 1 h in each buffer. Before determining enzy-
matic activity, samples were centrifuged for 3  min at 
16,000g. The residual activity was measured in 50  mM 
Tris–HCl buffer (pH 8) at room temperature using 
500 µM 2,6-DMP as a substrate and 5 mM H2O2 to initi-
ate the reaction.
P22‑CYP VLPs protection against protease degradation
The encapsulated and free CYP were treated with 10 U of 
trypsin per 1 mg of enzyme and incubated for 1 and 20 h 
at room temperature in 50 mM Tris–HCl buffer (pH 8). 
After incubation, the residual activity was determined as 
stated above.
Cell line and cell culture
Human cervix carcinoma cells (HeLa cells) were cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM) sup-
plemented with 10  % Fetal Bovine Serum (FBS, Bench-
Mark, Gemini Bio Products), 1 % Penicillin streptomycin 
(Sigma-Aldrich), 1  % l-glutamine and 1.5  g/l sodium 
bicarbonate. Cells were propagated in growth medium 
and maintained at 37 °C and 5 % CO2.
P22‑CYP VLPs transfection
Cell culture Petri dishes coated with Poly-d-lysine (Mat-
Tek P35GC1.5-10C) were used to seed 250,000 HeLa 
cells in DMEM media and incubated overnight at 37  °C 
and 5 % CO2. Transfection of P22-CYP nanoparticles was 
achieved using Lipofectamine 2000 reagent (Life tech-
nologies), according to [45] with few modifications to 
the manufacture’s protocol. Briefly, 3 µl of Lipofectamine 
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2000 was diluted in 100  µl of DMEM media without 
antibiotic and FBS (DMEM-SF) and 3.14  ×  1011 P22-
CYP nanoparticles were mixed with 100 µl of DMEM-SF 
media, both preparations were pre-incubated for 15 min 
at room temperature (RT). Afterwards, both samples 
were mixed for 30  min at RT. Prior to the addition of 
this transfection mixture to HeLa cell culture; cells were 
rinsed twice with sterile PBS buffer. The transfection 
mixture was added slowly on the top of the cell culture 
and let stand for 30 min at RT, then 1.8 ml of DMEM-SF 
media was added into HeLa cells culture and incubated 
for 4 h at 37 °C and 5 % CO2. After incubation, cell media 
was removed and the culture was rinsed once with PBS 
and 2  ml of complete DMEM media was added. HeLa 
cells transfected with VLP-CYP nanoparticles were incu-
bated overnight at 37 °C and 5 % CO2.
P22‑CYP VLP enzyme activity in vitro assay
CYP enzyme activity was assayed in HeLa cells (endog-
enous CYP activity) and in HeLa cells transfected with 
P22-CYP VLPs. The CYP activity was estimated by the 
transformation of 7-benzyloxy-4-trifluoromethylcou-
marin (BFC) in the fluorescent product 7-hydroxy-
4-[trifluoromethyl]-coumarin (HFC) according to [46] 
with some modifications. Briefly, cell culture media was 
discarded and 15 µl of 20 mM BFC diluted in 150 µl of 
complete DMEM media was added to each culture plate 
and incubated in darkness for 10  min at RT. Complete 
DMEM media was added up to 1.5 ml to each plate and 
further incubated for 30 min at 37 °C and 5 % CO2. Then, 
4.5 µl of 1 mM of hydrogen peroxide was added to each 
culture and incubated for 10 min at 37 °C and 5 % CO2. 
Cell culture plates were rinsed three times with PBS 
before the addition of 2  mL of complete DMEM media 
was added to each plate and incubated for 2  h at 37  °C 
and 5 % CO2 for further imaging analysis.
Confocal microscopy cell imaging
HeLa cell cultures treated with BFC reagent were fixed 
with 4 % formaldehyde-PBS solution at 4 °C for 15 min. 
After fixation, cells were permeabilized with 0.5 % Triton 
X/PBS for 15 min at 4 °C. Nuclear staining was achieved 
by incubated the cells with DAPI at 0.5  ng/ml in dark-
ness for 10 min at RT, followed by five washes with PBS. 
Nuclear staining with DAPI was also visualized with an 
inverted laser-scanning microscope Olympus FluoView 
FV1000 (Japan) using an argon ion laser for excitation 
at 405  nm wavelength and filters for emission of DAPI. 
BFC transformation into the fluorescent reagent HFC 
was detected using the GFP filter channel (excitation at 
488  nm and emission at 515–530  nm). Cells were visu-
alized with a 63  ×  (DIC), 1.4  N.A. planapochromatic 
oil immersion objective. The imaging parameters used 
produced no detectable background signal from any 
source other than from BFC and DAPI. Confocal images 
were captured using MetaMorph software for Olympus.
CYP activity quantification in HeLa cells transfected 
with P22‑CYP VLPs
The enzymatic activity of CYP in non-transfected and 
transfected HeLa cells with P22-CYP VLPs was measured 
spectrofluorimetrically. The fluorescence intensity origi-
nated by CYP-catalyzed transformation of BFC into HFC 
was monitored. After transfection, media from P22-CYP 
transfected cells and non-transfected HeLa cells (control 
cells) was replaced by 1.5 ml of complete DMEM media 
containing 15  µl of 20  mM BFC and incubated under 
darkness for 30 min at 37 °C and 5 % CO2. Then, cell cul-
ture plates were rinsed three times with PBS before the 
addition of 4.5 µl of 1 M of hydrogen peroxide and incu-
bated for 10 min at 37 °C and 5 % CO2. After incubation, 
cells were rinsed with PBS and harvested with trypsin/
EDTA treatment. Pelleted cells were counted and diluted 
in PBS to obtain 200,000 cells. Fluorescence intensity 
from transfected and non-transfected HeLa cells was 
measured in a fluorescence spectrophotomerer (Hitahchi 
F-7000), using an excitation source at 254 nm and emis-
sion measurement at 510 nm.
Abbreviations
BFC: 7‑benzyloxy‑4‑trifluoromethylcoumarin; CCMV: cowpea chlorotic mottle 
virus; CP: virus coat protein; CYP: cytochrome P450; CYP‑SP: fusion protein 
cytochrome P450‑scaffold protein; HFC: 7‑hydroxy‑4‑trifluoromethylcoumarin; 
HPLC‑MALS‑RI: high‑performance liquid chromatography equipped with 
multi‑angle laser light scattering (MALS) and refractive index (RI) detectors; 
IPTG: isopropyl‑β‑d‑1‑thiogalactopyranoside; P22‑CYP: capsid nanoparticle 
containing cytochrome P450; SP: virus scaffold protein; VLP: virus‑like particle.
Authors’ contributions
LSS performed most of experiments except tumor cell transfection. ATM and 
KJM carried out the cell transfection experiments. RDCN contributed to the 
design of encapsulation strategy. DPP and TD contributed on the design of 
the fusion protein and P22 capisde. RVD designed the study and is the PhD 
supervisor of LSS. All authors read and approved the final manuscript.
Authors’ information
An important part of this work has been performed under the direction of Dr. 
Trevor Douglas. The authors consider him as co‑corresponding author.
Author details
1 Instituto de Biotecnología, Universidad Nacional Autónoma de México, 
62250 Cuernavaca, Morelos, Mexico. 2 Centro de Nanociencias y Nano‑
tecnología, Universidad Nacional Autónoma de México, Km 107 carretera 
Tijuana‑Ensenada, 22860 Ensenada, Baja California, Mexico. 3 Cátedras CONA‑
CyT affiliated to CNyN‑UNAM, Ensenada, Mexico. 4 Department of Chemistry 
and Biochemistry, University of Texas at Tyler, Tyler 75799, TX, USA. 5 Depart‑
ment of Chemistry, Indiana University, Bloomington, IN 47405, USA. 
Acknowledgements
This work has been founded by the National Council of Science and Technol‑
ogy of Mexico (LSS scholarship and research stay), SEP‑CONACYT (165633), 
PAPIIT‑UNAM (IN200814) and supported in part by a grant from the National 
Science Foundation (NSF‑BMAT DMR‑1435460). We thank Dr. Katrin Quester 
Page 10 of 10Sánchez‑Sánchez et al. J Nanobiotechnol  (2015) 13:66 
for her technical assistance. Dr. Juarez‑Moreno is member of the International 
Network in Bionanotechnology (CONACyT), Mexico.
Competing interests
The authors declared that they have no competing interests.
Received: 10 July 2015   Accepted: 24 September 2015
References
 1. Vellard M. The enzyme as drug: application of enzymes as pharmaceuti‑
cals. Curr Opin Biotechol. 2003;14:444–50.
 2. Kang TS, Stevens RC. Structural aspects of therapeutic enzymes to treat 
metabolic disorders. Hum Mutat. 2009;30:1591–610.
 3. Maximov V, Reukov V, Vertegel AA. Targeted delivery of therapeutic 
enzymes. J Drug Deliv Sci Technol. 2009;19:311–20.
 4. Beutler E. Enzyme replacement therapy. Trends Biochem Sci. 1981;6:95–7.
 5. Lachmann RH. Enzyme replacement therapy for lysosomal storage 
diseases. Curr Opin Pediatr. 2011;23:588–93.
 6. Kishnani PS, Beckemeyer AA. New therapeutic approaches for Pompe dis‑
ease: enzyme replacement therapy and beyond. Pediatr Endocrinol Rev. 
2014;12(Suppl 1):114–24.
 7. Satchi R, Connors TA, Duncan R. PDEPT: polymer‑directed enzyme prod‑
rug therapy. Brit J Cancer. 2001;85:1070–6.
 8. Bagshawe KD. Antibody‑directed enzyme prodrug therapy (ADEPT) for 
cancer. Expert Rev Anticancer Ther. 2006;6:1421–31.
 9. Schellmann N, Deckert PM, Bachran D, Fuchs H, Bachran C. Targeted 
enzyme prodrug therapies. Mini Rev Med Chem. 2010;10:887–904.
 10. Torchilin V. Intracellular delivery of protein and peptides therapeutics. 
Drug Discov Today Technol. 2008;5:e95–103.
 11. Pokorski JK, Steinmetz NF. The art of engineering viral nanoparticles. Mol 
Pharm. 2011;8:29–43.
 12. Comellas‑Aragones M, Engelkamp H, Claessen VI, Sommerdijk NA, Rowan 
AE, Christianen PC, Maan JC, Verduin BJ, Cornelissen JJ, Nolte RJ. A virus‑
based single‑enzyme nanoreactor. Nat Nanotechnol. 2007;2:635–9.
 13. Fiedler J, Brown S, Brown SD, Lau JL, Finn MG. RNA‑directed pack‑
aging of enzymes within virus‑like particles. Angew Chem Int Ed. 
2010;49:9648–51.
 14. Minten IJ, Claessen V, Blank K, Rowan AE, Nolte RJ, Cornelissen JJ. Catalytic 
capsids: the art of confinement. Chem Sci. 2011;2:358–62.
 15. Patterson D, Prevelige PE, Douglas T. Nanoreactors by programmed 
enzyme encapsulation inside the capsid of the bacteriophage P22. ACS 
Nano. 2012;6:5000–9.
 16. Patterson D, Shwarz B, El‑Boubbou K, Oost J, Prevelige PE, Douglas T. 
Virus‑like particle nanoreactors: programmed encapsulation of the 
thermostable CelB glycosidase inside the P22 capsid. Soft Matter. 
2012;8:10158–66.
 17. O’Neil A, Prevelige PE Jr, Douglas T. Stabilizing viral nano‑reactors for 
nerve‑agent degradation. Biomater Sci. 2013;1:881–6.
 18. Patterson DP, Schwarz B, Waters RS, Gedeon T, Douglas T. Encapsulation of 
an enzyme cascade within the bacteriophage P22 virus‑like particle. ACS 
Chem Biol. 2014;9:359–65.
 19. Teschke C, Parent K. ‘Let the phage do the work’: using the phage P22 
coat protein structures as a framework to understand its folding and 
assembly mutants. Virology. 2010;401:119–30.
 20. O’Neil A, Reichhardt C, Johnson B, Prevelige PE Jr, Douglas T. Geneti‑
cally programmed in vivo packaging of protein cargo and its controlled 
release from bacteriophage P22. Angew Chem Int Ed. 2011;50:7425–8.
 21. Cirino PC, Arnold FH. A Self‑sufficient peroxide‑driven hydroxylation 
biocatalyst. Angew Chem Int Ed. 2003;42:3299–301.
 22. Sanchez‑Sanchez L, Roman R, Vazquez‑Duhalt R. Pesticide transforma‑
tion by a variant of CYPBM3 with improved peroxygenase activity. Pestic 
Biochem Physiol. 2012;102:169–74.
 23. Carmichael AB, Wong LL. Protein engineering of Bacillus megaterium 
CYP102. The oxidation of polycyclic aromatic hydrocarbons. Eur J Bio‑
chem. 2001;268:3117–25.
 24. Di Nardo G, Fantuzzi A, Sideri A, Panicco P, Sassone C, Giunta C, Gilardi G. 
Wild‑type CYP102A1 as a biocatalyst: turnover of drugs usually metabo‑
lised by human liver enzymes. J Biol Inorg Chem. 2007;12:313–23.
 25. Sanchez‑Sanchez L, Cadena‑Nava RD, Palomares LA, Ruiz‑Garcia J, Koay 
MST, Cornelissen JJMT, Vazquez‑Duhalt R. Chemotherapy pro‑drug 
activation by biocatalytic virus‑like nanoparticles containing cytochrome 
P450. Enzyme Microb Tech. 2014;60:24–31.
 26. Guengerich FP, Martin MV, Sohl CD, Cheng Q. Measurement of 
cytochrome P450 and NADPH‑cytochrome P450 reductase. Nat Protoc. 
2009;4:1245–51.
 27. Egawa T, Hishiki T, Ichikawa Y, Kanamori Y, Shimada H, Takahashi S, 
Kitagawa T, Ishimura Y. Refolding processes of cytochrome P450cam from 
ferric and ferrous acid forms to the native conformation. J Biol Chem. 
2004;279:32008–17.
 28. Chen YP, Chen CT, Hung Y, Chou CM, Liu TP, Liang MR, Chen CT, Mou CY. A 
new strategy for intracellular delivery of enzyme using mesoporous silica 
nanoparticles: superoxide dismutase. J Am Chem Soc. 2013;135:1516–23.
 29. Estrada LH, Chu S, Champion JA. Protein nanoparticles for intracellular 
delivery of therapeutic enzymes. Pharm Nanotechnol. 2014;103:1863–71.
 30. Cho EC, Zhang Q, Xia Y. The effect of sedimentation and diffusion on cel‑
lular uptake of gold nanoparticles. Nat Nanotechnol. 2011;6:385–91.
 31. Inoue T, Kawano MA, Takahashi RU, Tsukamoto H, Enomoto T, Imai T, 
Kataoka K, Handa H. Engineering of SV40‑based nano‑capsules for deliv‑
ery of heterologous proteins as fusions with the minor capsid proteins 
VP2/3. J Biotechnol. 2008;134:181–92.
 32. Li HY, Poulos TL. Fatty acid metabolism, conformational change, and 
electron transfer in cytochrome P‑450BM‑3. Biochim Biophys Acta. 
1999;1441:141–9.
 33. Maurer SC, Schulze H, Schmid RD, Urlacher V. Immobilisation of P450BM‑3 
and an NADP(+) cofactor recycling system: towards a technical applica‑
tion of heme‑containing monooxygenases in fine chemical synthesis. 
Adv Synth Catal. 2003;345:802–10.
 34. Zhao L, Gueven G, Li Y, Schwaneberg U. First steps towards a Zn/Co(III)
sep‑driven P450 BM3 reactor. App Microbiol Biot. 2011;91:989–99.
 35. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in 
cancer progression. Nat Rev Cancer. 2002;2:161–74.
 36. Simon C, Schaepe S, Breunig K, Liliea H. Production of polyomavirus‑like 
particles in a Klgal80 knockout strain of the yeast Kluyveromyces lactis. 
Prep Biochem Biotechnol. 2013;43:217–35.
 37. Simon C, Klose T, Herbst S, Han BG, Sinz A, Glaeser RM, Stubbs MT, Lilie H. 
Disulfide linkage and structure of highly stable yeast‑derived virus‑like 
particles of murine polyomavirus. J Biol Chem. 2014;289:10411–8.
 38. Sorkin A, Zastrow M. Signal transduction and endocytosis: close encoun‑
ters of many kinds. Nat Rev Mol Cell Biol. 2002;3:600–14.
 39. Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim‑Hashim A, 
Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, et al. Acidity gener‑
ated by the tumor microenvironment drives local invasion. Cancer Res. 
2013;73:1524–35.
 40. Jugminder S, Chawla JV, Amij MM. Cellular uptake and concentrations 
of tamoxifen upon administration in poly(ε‑caprolactone) nanoparticles. 
AAPS PharmSci. 2003;5:28–34.
 41. Steichen SD, Caldorera‑Moore M, Peppas NA. A review of current nano‑
particle and targeting moieties for the delivery of cancer therapeutics. 
Eur J Pharm Sci. 2013;48:416–27.
 42. Wanga M, Thanoua M. Targeting nanoparticles to cancer. Pharmacol Res. 
2010;62:90–9.
 43. Ruoslahti E. Peptides as targeting elements and tissue penetration 
devices for nanoparticles. Adv Mater. 2012;24:3747–56.
 44. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, 
Bairoch A. Protein Identification and Analysis Tools on the ExPASy Server. 
In: Walker JM, editor. The Proteomics Protocol Handbook. New Jersey: 
Humana Press; 2005. p. 571–607.
 45. Azizgolshani O, Garmann RF, Cadena‑Nava RD, Knobler CM, Gelbart WM. 
Reconstituted plant viral capsids can release genes to mammalian cells. 
Virology. 2013;441:12–7.
 46. Arora V, Cate ML, Ghosh C, Iversen PL. Phosphorodiamidate morpholino 
antisense oligomers inhibit expression of human cytochrome P450 3A4 
and alter selected drug metabolism. Drug Metab Dispos. 2002;30:757–62.
